Inflammation as a central mechanism in Alzheimer's disease Tập 4 Số 1 - Trang 575-590 - 2018
Jefferson W. Kinney, Shane M. Bemiller, Andrew S. Murtishaw, Amanda M. Leisgang, Arnold Salazar, Bruce T. Lamb
AbstractAlzheimer's disease (AD) is a progressive neurodegenerative disorder
that is characterized by cognitive decline and the presence of two core
pathologies, amyloid β plaques and neurofibrillary tangles. Over the last
decade, the presence of a sustained immune response in the brain has emerged as
a third core pathology in AD. The sustained activation of the brain's resident
macrophages (micro... hiện toàn bộ
Alzheimer's disease drug development pipeline: 2018 Tập 4 Số 1 - Trang 195-214 - 2018
Jeffrey L. Cummings, Garam Lee, Aaron Ritter, Kate Zhong
AbstractIntroductionTreatments for Alzheimer's disease (AD) are needed due to
the growing number of individuals with preclinical, prodromal, and dementia
forms of AD. Drug development for AD therapies can be examined by inspecting the
drug development pipeline as represented on
clinicaltrials.gov.MethodsClinicaltrials.gov was assessed as of January 30, 2018
to determine AD therapies represented in... hiện toàn bộ
Alzheimer's disease drug development pipeline: 2017 Tập 3 Số 3 - Trang 367-384 - 2017
Jeffrey L. Cummings, Garam Lee, Travis Mortsdorf, Aaron Ritter, Kate Zhong
AbstractIntroductionThere is an urgent need to develop new treatments for
Alzheimer's disease (AD) and to understand the drug development process for new
AD therapies.MethodsWe assessed the agents in the AD pipeline as documented in
clinicaltrials.gov for phase I, phase II, and phase III, accessed
1/5/2017.ResultsThere are 105 agents in the AD treatment development pipeline,
of which 25 agents are... hiện toàn bộ
Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain health Tập 3 Số 3 - Trang 291-300 - 2017
Michael J. Wheeler, Paddy C. Dempsey, Megan S. Grace, Kathryn A. Ellis, Paul A. Gardiner, Daniel J. Green, David W. Dunstan
AbstractCognitive decline leading to dementia represents a global health burden.
In the absence of targeted pharmacotherapy, lifestyle approaches remain the best
option for slowing the onset of dementia. However, older adults spend very
little time doing moderate to vigorous exercise and spend a majority of time in
sedentary behavior. Sedentary behavior has been linked to poor glycemic control
and... hiện toàn bộ
Amyloid‐associated increases in longitudinal report of subjective cognitive complaints Tập 4 - Trang 444-449 - 2018
Rebecca E. Amariglio, Rachel F. Buckley, Elizabeth C. Mormino, Gad A. Marshall, Keith A. Johnson, Dorene M. Rentz, Reisa A. Sperling
AbstractIntroductionTo investigate whether baseline subjective cognitive
complaints (SCCs) predict longitudinal decline on neuropsychological testing and
whether SCC increases longitudinally, in the setting of high levels of amyloid
burden.MethodsTwo hundred seventy‐nine clinically normal older participants
(mean age = 73.7 ± 6.1 years) from the Harvard Aging Brain Study, a cohort of
community‐dwe... hiện toàn bộ
Accelerating drug development for Alzheimer's disease through the use of data standards Tập 3 - Trang 273-283 - 2017
Jon Neville, Steve Kopko, Klaus Romero, Brian Corrigan, Bob Stafford, Elizabeth LeRoy, Steve Broadbent, Martin Cisneroz, Ethan Wilson, Eric Reiman, Hugo Vanderstichele, Stephen P. Arnerić, Diane Stephenson
AbstractIntroductionThe exceedingly high rate of failed trials in Alzheimer's
disease (AD) calls for immediate attention to improve efficiencies and learning
from past, ongoing, and future trials. Accurate, highly rigorous standardized
data are at the core of meaningful scientific research. Data standards allow for
proper integration of clinical data sets and represent the essential foundation
for... hiện toàn bộ
A blood‐based nutritional risk index explains cognitive enhancement and decline in the multidomain Alzheimer prevention trial Tập 5 - Trang 953-963 - 2019
Gene L. Bowman, Hiroko H. Dodge, Sophie Guyonnet, Nina Zhou, Juliana Donohue, Aline Bichsel, Jeroen Schmitt, Claudie Hooper, Tamas Bartfai, Sandrine Andrieu, Bruno Vellas
AbstractIntroductionMultinutrient approaches may produce more robust effects on
brain health through interactive qualities. We hypothesized that a blood‐based
nutritional risk index (NRI) including three biomarkers of diet quality can
explain cognitive trajectories in the multidomain Alzheimer prevention trial
(MAPT) over 3‐years.MethodsThe NRI included erythrocyte n‐3 polyunsaturated
fatty acids ... hiện toàn bộ
Adherence/Retention Alzheimer's Prevention Initiative Colombia Plan Tập 4 - Trang 283-287 - 2018
Silvia Rios-Romenets, Natalia Acosta-Baena, Liliana Lopez, Lucia Madrigal-Zapata, Helen Street, Laura Jakimovich, Jessica B. Langbaum, William Cho, Eric M. Reiman, Pierre N. Tariot, Francisco Lopera
AbstractIntroductionThe Alzheimer's Prevention Initiative Colombia Trial is a
collaborative project involving the Neurosciences Group of Antioquia,
Genentech/Roche, and the Banner Alzheimer's Institute, studying whether
crenezumab can delay or prevent the clinical onset of Alzheimer's disease in
cognitively unimpaired individuals who carry the PSEN1 E280A mutation. In an
effort to optimize partici... hiện toàn bộ
Poor cerebrovascular function is an early marker of cognitive decline in healthy postmenopausal women Tập 2 - Trang 162-168 - 2016
Rachel H.X. Wong, Hamish M. Evans, Peter R.C. Howe
AbstractIntroductionImpairment of cerebrovascular function becomes evident after
menopause. No study has yet explored relationships between deficits in
cerebrovascular function, cognitive performance, and mood in postmenopausal
women.MethodCerebrovascular function was assessed in 80 healthy postmenopausal
women by monitoring blood flow velocity (BFV) in the middle and posterior
cerebral arteries u... hiện toàn bộ